Counterfeit or stolen medicine reports have risen by as much as 374% in some markets, driving calls for anti-counterfeiting packaging tailored to local risk, regulation and supply-chain infrastructure.
EU and US drugmakers already operate under serialization and tamper-evidence rules, so the focus there is shifting from basic compliance to faster line speeds, better data capture and packaging that supports automation.
Emerging markets face weaker enforcement and more fragmented distribution, making overt, tool-free verification features more important because patients, pharmacists and distributors may lack scanning technology.
Layered systems combining overt, covert, forensic and digital tools—such as holograms, microtext, QR codes, NFC and RFID—are presented as the most effective way to match protection to product and market risk.
That approach also broadens packaging's role beyond anti-counterfeiting, turning authentication data into supply-chain visibility, recall support and patient engagement rather than relying on one global standard.
As nations weaponize supply chains, is your medicine's packaging the last defense against geopolitical threats?
With new EU cybersecurity rules, is the biggest threat to your medicine now digital instead of physical?
Counterfeit Medicines Surge to $400 Billion: Global Threats and the Race for Secure, Sustainable Pharma Packaging
Overview
Counterfeit medicines are rising rapidly worldwide, creating a crisis that threatens both public health and the global economy. The counterfeit drug market now generates hundreds of billions of dollars each year, draining money from legitimate businesses and causing significant economic losses. Most alarmingly, fake drugs are responsible for about one million deaths annually, showing the severe human cost of this illicit trade. The spread of counterfeit medicines not only damages economies but also undermines trust in healthcare systems and the reputation of genuine manufacturers, making this a critical issue that demands urgent action.